Center for Clinical Transfusion Research, Sanquin Research, Leiden, the Netherlands; Department of Pediatrics, Division of Neonatology, Leiden University Medical Center, Leiden, the Netherlands.
Department of Pediatrics, Division of Neonatology, Leiden University Medical Center, Leiden, the Netherlands.
Am J Obstet Gynecol. 2020 Jul;223(1):119.e1-119.e10. doi: 10.1016/j.ajog.2020.01.028. Epub 2020 Jan 21.
Infants with severe hemolytic disease of the fetus and newborn often require 1 or multiple intrauterine transfusions to treat fetal anemia. Intrauterine transfusions may have an inhibiting effect on fetal and neonatal erythropoiesis.
To quantify the effect of 1 or multiple intrauterine transfusions on the fetal erythropoiesis by assessing the fetal reticulocyte counts in a population with severe hemolytic disease of the fetus and newborn.
This was an observational cohort study in infants admitted to the Leiden University Medical Center who received 1 or multiple intrauterine transfusions for hemolytic disease of the fetus and newborn caused by (Rh)D or Kell antibodies and were born between January 2005 and December 2018.
A total of 235 patients were included, of whom 189 were patients with D-mediated hemolytic disease of the fetus and newborn and 46 with Kell-mediated hemolytic disease of the fetus and newborn. Absolute fetal reticulocyte count in D-mediated hemolytic disease of the fetus and newborn declined exponentially over the course of consecutive intrauterine transfusions, with a 62% decline after 1 intrauterine transfusion (95% confidence interval, 56-67). A similar exponential decline was observed in Kell-mediated hemolytic disease of the fetus and newborn, with 32% (95% confidence interval, 19-45) decline after 1 intrauterine transfusion. This decline was not associated with the varying gestational age at the time of the first intrauterine transfusion or the total number of intrauterine transfusions. The number of red blood cell transfusions for postnatal anemia was greater for infants with D and Kell-mediated hemolytic disease of the fetus and newborn with >2 intrauterine transfusions (median of 3 [interquartile range, 2-3] vs 2 [interquartile range, 1-3], P=.035, in D-mediated disease and median of 2 [interquartile range, 1-2] vs 1 [interquartile range, 1-1], P<.001, in Kell-mediated disease). Infants born after >2 intrauterine transfusions less often required exchange transfusion in D-mediated hemolytic disease of the fetus and newborn (19/89 [21%] vs 31/100 [31%], P=.039), compared with infants with 1-2 intrauterine transfusions.
Treatment with intrauterine transfusions causes an exponential decrease in fetal reticulocyte counts in both D- and Kell-mediated hemolytic disease of the fetus and newborn. Suppression of the compensatory erythropoiesis leads to prolonged postnatal anemia and an increased requirement of red blood cell transfusions after birth.
患有严重胎儿和新生儿溶血病的婴儿通常需要 1 次或多次宫内输血来治疗胎儿贫血。宫内输血可能会对胎儿和新生儿的红细胞生成产生抑制作用。
通过评估患有严重胎儿和新生儿溶血病的人群中的胎儿网织红细胞计数,来量化 1 次或多次宫内输血对胎儿红细胞生成的影响。
这是一项观察性队列研究,纳入了在莱顿大学医学中心接受 1 次或多次宫内输血治疗因 Rh)D 或 Kell 抗体引起的胎儿和新生儿溶血病的婴儿,这些婴儿出生于 2005 年 1 月至 2018 年 12 月。
共纳入 235 例患者,其中 189 例为 D 介导的胎儿和新生儿溶血病患者,46 例为 Kell 介导的胎儿和新生儿溶血病患者。D 介导的胎儿和新生儿溶血病患者的绝对胎儿网织红细胞计数在连续的宫内输血过程中呈指数下降,1 次宫内输血后下降 62%(95%置信区间,56%-67%)。在 Kell 介导的胎儿和新生儿溶血病中也观察到类似的指数下降,1 次宫内输血后下降 32%(95%置信区间,19%-45%)。这种下降与首次宫内输血时的不同胎龄或宫内输血总数无关。与 1-2 次宫内输血的患者相比,接受 >2 次宫内输血的 D 和 Kell 介导的胎儿和新生儿溶血病患者的新生儿期贫血后需要更多的红细胞输血(中位数为 3[四分位距,2-3] vs 2[四分位距,1-3],P=.035,在 D 介导的疾病中;中位数为 2[四分位距,1-2] vs 1[四分位距,1-1],P<.001,在 Kell 介导的疾病中)。与 1-2 次宫内输血的患者相比,接受 >2 次宫内输血的 D 介导的胎儿和新生儿溶血病患者的婴儿在出生后较少需要换血治疗(19/89[21%] vs 31/100[31%],P=.039)。
宫内输血治疗会导致 D 型和 Kell 型胎儿和新生儿溶血病患者的胎儿网织红细胞计数呈指数下降。抑制代偿性红细胞生成会导致新生儿期贫血持续时间延长,并增加出生后红细胞输血的需求。